Comparative Pharmacology
Head-to-head clinical analysis: HEAD SHOULDERS CONDITIONER versus SPORANOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEAD SHOULDERS CONDITIONER versus SPORANOX.
HEAD & SHOULDERS CONDITIONER vs SPORANOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable; this is a cosmetic conditioner. No pharmacological mechanism.
Inhibits fungal cytochrome P450 (CYP450)-dependent lanosterol 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Not applicable. Head & Shoulders Conditioner is a cosmetic product for external use on hair and scalp; no systemic dosing.
200 mg orally twice daily for 3-7 days; for onychomycosis: 200 mg orally once daily for 12 weeks.
None Documented
None Documented
Not applicable for systemic elimination; local retention on hair/scalp lasts until next wash (typically 24-48 hours).
The terminal elimination half-life of itraconazole ranges from 21 to 35 hours for single doses, increasing to approximately 34 to 42 hours at steady state. The half-life of the active metabolite, hydroxyitraconazole, is similar. This long half-life allows for once-daily or twice-daily dosing in most indications.
Renal (urine): <1% unchanged; biliary/fecal: <1% as parent compound; majority remains on hair/scalp and is removed via washing and shedding. Systemic absorption negligible.
Itraconazole is extensively metabolized in the liver via CYP3A4 to active metabolites, including hydroxyitraconazole. The parent drug and metabolites are primarily excreted in feces (approximately 54%) and urine (approximately 35%), with less than 1% of the dose excreted unchanged in urine.
Category C
Category C
Antifungal/Antidandruff
Antifungal